Compare GNK & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNK | MRVI |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2005 | 2020 |
| Metric | GNK | MRVI |
|---|---|---|
| Price | $27.15 | $7.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $19.00 | $4.13 |
| AVG Volume (30 Days) | 573.7K | ★ 4.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $342,054,000.00 | $185,743,000.00 |
| Revenue This Year | $21.15 | $12.54 |
| Revenue Next Year | $1.41 | $7.87 |
| P/E Ratio | $46.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.56 | $2.37 |
| 52 Week High | $27.76 | $9.42 |
| Indicator | GNK | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 51.62 |
| Support Level | $22.78 | $5.37 |
| Resistance Level | $27.76 | $7.44 |
| Average True Range (ATR) | 0.91 | 0.52 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 74.04 | 45.89 |
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.